AOA Dx vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Molecular diagnostics company developing novel biomarker detection tests for earlier disease identification; proprietary antibody-based assays targeting clinical laboratory deployment.
About
AOA Dx (formerly known under a different name) is a molecular diagnostics company developing novel diagnostic tests for earlier and more accurate disease detection, focusing on underserved testing gaps in clinical settings. The company applies innovative biomarker detection approaches to improve diagnostic accuracy in categories where current testing misses significant patient populations or delivers delayed results.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.